.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
Federal Trade Commission
Johnson and Johnson
US Army
Novartis
Medtronic
McKesson
Chubb
Express Scripts

Generated: December 18, 2017

DrugPatentWatch Database Preview

Novartis Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS PHARMS, and what generic alternatives to NOVARTIS PHARMS drugs are available?

NOVARTIS PHARMS has seventy approved drugs.

There are one hundred and twenty US patents protecting NOVARTIS PHARMS drugs and there have been six Paragraph IV challenges on NOVARTIS PHARMS drugs in the past three years.

There are one thousand eight hundred and fifty patent family members on NOVARTIS PHARMS drugs in seventy-three countries and one hundred and sixty-six supplementary protection certificates in fifteen countries.

Summary for Novartis Pharms

International Patents:1850
US Patents:120
Tradenames:60
Ingredients:50
NDAs:70
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-001May 29, 2013RXYesNo► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-001Nov 20, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpCIPRODEXciprofloxacin; dexamethasoneSUSPENSION/DROPS;OTIC021537-001Jul 18, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpMOXEZAmoxifloxacin hydrochlorideSOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010AT2RXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpKISQALIribociclib succinateTABLET;ORAL209092-001Mar 13, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpKISQALIribociclib succinateTABLET;ORAL209092-001Mar 13, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-005Nov 16, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpZOFRANondansetron hydrochlorideTABLET;ORAL020103-003Aug 27, 1999► Subscribe► Subscribe
Novartis Pharms CorpZOFRANondansetron hydrochlorideTABLET;ORAL020103-001Dec 31, 1992► Subscribe► Subscribe
Novartis Pharms CorpVIGAMOXmoxifloxacin hydrochlorideSOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003► Subscribe► Subscribe
Novartis Pharms CorpZOFRAN ODTondansetronTABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 1999► Subscribe► Subscribe
Novartis Pharms CorpEMADINEemedastine difumarateSOLUTION/DROPS;OPHTHALMIC020706-001Dec 29, 1997► Subscribe► Subscribe
Novartis Pharms CorpBETOPTIC Sbetaxolol hydrochlorideSUSPENSION/DROPS;OPHTHALMIC019845-001Dec 29, 1989► Subscribe► Subscribe
Novartis Pharms CorpEMADINEemedastine difumarateSOLUTION/DROPS;OPHTHALMIC020706-001Dec 29, 1997► Subscribe► Subscribe
Novartis Pharms CorpIOPIDINEapraclonidine hydrochlorideSOLUTION/DROPS;OPHTHALMIC020258-001Jul 30, 1993► Subscribe► Subscribe
Novartis Pharms CorpMOXEZAmoxifloxacin hydrochlorideSOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010► Subscribe► Subscribe
Novartis Pharms CorpZOFRANondansetron hydrochlorideINJECTABLE;INJECTION020007-001Jan 4, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for NOVARTIS PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
deferasiroxTablets180 mgJADENU4/28/2016
travoprostOphthalmic Solution0.003%IZBA12/30/2015
nepafenacOphthalmic Suspension0.3%ILEVRO12/21/2015
deferasiroxTablets180 mgJADENU10/23/2015
deferasiroxTablets90 mg and 360 mgJADENU10/19/2015
olopatadine hydrochlorideOphthalmic Solution0.7%PAZEO9/10/2015
difluprednateOphthalmic Emulsion0.05%DUREZOL5/1/2014
eltrombopag olamineTablets12.5 mg and 25 mgPROMACTA2/4/2014
eltrombopag olamineTablets50 mg and 75 mgPROMACTA1/7/2014
ciprofloxacin and dexamethasoneOtic Suspension0.3%/0.1%CIPRODEX7/31/2012
moxifloxacin hydrochlorideOphthalmic Solution10.5%MOXEZA2/29/2012
argatroban in sodium chlorideInjection1 mg/mL, 50 mL vialsARGATROBAN12/16/2011
lapatinib ditosylateTablets250 mgTYKERB3/14/2011
olopatadine hydrochlorideNasal Spray0.665 mg/ SprayPATANASE6/29/2009
tobramycinInhalation Solution300 mg/5 mLTOBI6/29/2009
travoprost (preserved)Ophthalmic Solution0.00%TRAVATAN Z2/19/2009
olopatadine hydrochlorideOphthalmic Solution0.20%PATADAY9/8/2008
argatrobanInjection100 mg/mL, 2.5 mL vialsARGATROBAN9/24/2007
olopatadine hydrochlorideOphthalmic Solution0.10%PATANOL7/17/2006
letrozoleTablets2.5 mgFEMARA3/2/2006
moxifloxacin hydrochlorideOphthalmic0.50%VIGAMOX12/22/2005
ondansetron hydrochlorideOral Solution4 mg/5 mLZOFRAN12/20/2004

Non-Orange Book Patents for Novartis Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,410,2662,4-pyrimidinediamine compounds and their uses► Subscribe
8,263,590Pyrimidine derivatives► Subscribe
8,445,479Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity► Subscribe
8,822,6852,4-pyrimidinediamine compounds and their uses► Subscribe
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
7,709,012Ophthalmic compositions containing a synergistic combination of two polymers► Subscribe
8,088,8133'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)► Subscribe
7,825,116N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines► Subscribe
8,188,037Microparticles comprising somatostatin analogues► Subscribe
7,329,6722,4-pyrimidinediamine compounds and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Pharms Drugs

Country Document Number Estimated Expiration
Eurasian Patent Organization201290149► Subscribe
Morocco33746► Subscribe
Brazil0307355► Subscribe
New Zealand522989► Subscribe
Peru02302000► Subscribe
South Korea20130130028► Subscribe
Poland393259► Subscribe
Portugal2116227► Subscribe
Ukraine66827► Subscribe
Colombia6260058► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0914118/01Switzerland► SubscribePRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
890Luxembourg► SubscribePRODUCT NAME: PANOBINSTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE , OU UN DERIVE DE CELUI-CI (FARYDAK); FIRST REGISTRATION: 20150901
0248Netherlands► Subscribe300248, 20170624, EXPIRES: 20210827
2015 00050Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 20150508
2008000048Germany► SubscribePRODUCT NAME: LAPATINIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/07/440/001-002 20080610
C0045France► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
00716Netherlands► SubscribePRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
2015000098Germany► SubscribePRODUCT NAME: PANOBINOSTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER DERIVAT HIERVON; REGISTRATION NO/DATE: EU/1/15/1023 20150828
00540Netherlands► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
2004012Lithuania► SubscribePRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Baxter
Cantor Fitzgerald
Cerilliant
Fuji
Daiichi Sankyo
Harvard Business School
Fish and Richardson
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot